Cost-effectiveness in clinical cardiology: II. Preventive strategies and arrhythmia therapies

Chest

Volumn 110, Issue 1, 1996, Pages 256-262

  Simmons, Jeffrey ^a   Chakko, Simon ^a   Willens, Howard ^a   Kessler, Kenneth M ^a  

^a NONE

Author keywords

antiarrhythmic agents; arrhythmia; cholesterol; coronary artery disease; cost effective; hypertension; ICD therapy; syncope

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; COLESTYRAMINE; HYDROCHLOROTHIAZIDE; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NIFEDIPINE; PROPRANOLOL; SIMVASTATIN;

ADULT; ARTICLE; CARDIOLOGY; CARDIOVERSION; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; ELECTROCARDIOGRAPHY; EXERCISE; HEALTH CARE COST; HEART ARREST; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; SECONDARY PREVENTION; SMOKING CESSATION; TELEMETRY;

EID: 0029892593     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.110.1.256     Document Type: Article

References (60)

1. Willens HJ, Chakko S, Simmons J, et al. Cost-effectiveness in clinical cardiology: I. Coronary artery disease and congestive heart failure. Chest 1996; 109:1359-69
2. Kassirer JP, Moskowitz AJ, Lau J, et al. Decision analysis: a progress report. Ann Intern Med 1987; 106:275-91
3. Goldman L. Cost-effective strategies in cardiology. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. Philadelphia, PA: W.B. Saunders Company, 1992; 1694-707
4. Pauker SC, Kassiver JP. Decision analysis. N Engl J Med 1987; 316:250-58
5. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989; 262:2879-86
6. Kupersmith J, Holmes-Rovner M, Hogan A, et al. Cost-effectiveness analysis in heart disease: I. General principles. Prog Cardiovasc Dis 1994; 37:161-84
7. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113:147-54
8. Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med 1993; 329:1271-74
9. Tanenbaum SJ. Sounding board what physicians know. N Engl J Med 1993; 329:1268-71
10. Powell KE, Thompson PD, Caspersen CJ, et al. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health 1987; 8:253-87
11. Jacoby DB. Letter to the editor. N Engl J Med 1986; 315:1986
12. Hatziandreu EI, Koplan JP, Weinstein MC, et al. A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health 1988; 78:1417-21
13. Shepard RJ, Corey P, Renzland P, et al. The influence of an employee fitness and lifestyle modification upon medical care costs. Can J Public Health 1982; 73:259
14. Sox HC, Blatt MA, Higgins MC, et al. Medical decision making. Stoneham, Mass: Butterworth, 1988; 1-23
15. Patterson RE, Eng C, Horowitz SF, et al. Bayesian comparison of cost-effectiveness of different clinical approaches to diagnose coronary artery disease. J Am Coll Cardiol 1984; 4:278-89
16. Patterson RE, Eisner RL, Horowitz SF. Comparison of cost-effectiveness and utility of exercise ECG, single photon emission computer tomography, positron emission tomography and coronary angiography for diagnosis of coronary artery disease. Circulation 1995; 91:54-65
17. Stason WB, Fineberg HV. Implications of alternative strategies to diagnose coronary artery disease. Circulation 1982; 66(suppl II-I):III80-III86
18. Doubilet P, McNeil BJ, Weinstein MC. The decision concerning coronary angiography in patients with chest pain: a cost-effectiveness analysis. Med Decis Making 1985; 5:293-309
19. Lee TH, Fukui T, Weinstein MC, et al. Cost-effectiveness of screening strategies for left main coronary artery disease in patients with stable angina. Med Decis Making 1988; 8:268-78
20. Kupersmith J, Holmes-Rovner M, Hogan A, et al. Cost-effectiveness analysis in heart disease: II. Preventive therapies. Prog Cardiovasc Dis 1995; 37:243-71
21. Russell LB. The role of prevention in health reform. N Engl J Med 1993; 329:352-54
22. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health 1985; 6:41-63
23. Oster G, Epstein AM. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA 1987; 258:2381-87
24. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs. JAMA 1990; 264:3025-33
25. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265:1145-51
26. Martens LL, Rutten FFH, Erkelens DW. Cost effectiveness of cholesterol-lowering therapy in the Netherlands. Am J Med 1989; 87(suppl 4A):54S-58S
27. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317:1237
28. Kinosian BP, Eisenberg JM. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. JAMA 1988; 259:2249-54
29. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation 1992; 85:1960-68
30. Himmelstein DU, Woolhandler MD. Free care, cholestyramine, and health policy. N Engl J Med 1984; 311:1511-14
31. Smith SC, Blair SN, Criqui MH, et al. The Secondary Prevention panel. Preventing heart attack and death in patients with coronary disease. Circulation 1995; 92:2-4
32. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296:732-39
33. Stevens RD, Bingley LJ, Boger M, Variability in the management of hypertension and cost-effectiveness: methodology, community care results and potential cost reductions. Soc Sci Med 1984; 18:767-74
34. Littenberg B, Garber AM, Sox HC. Screening for hypertension. Ann Intern Med 1990; 112:192-292
35. Weinstein MC, Stason WB. Hypertension-a policy perspective. Cambridge, Mass: Harvard University, 1976; 1-10
36. Edelson JT, Weinstein MC, Tosteson AN, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263:407-13
37. Cantor JC, Morisky De, Green LW, et al. Cost-effectiveness of educational interventions to improve patient outcomes in blood pressure controls. Prev Med 1985; 14:783-800
38. McNeil BJ, Varady PD, Burrows BA, et al. Measures of clinical efficacy: cost-effectiveness calculation in the diagnosis and treatment of hypertensive renovascular disease. N Engl J Med 1975; 293:216-21
39. England WL, Grim CE, Weinberger MH, et al. Cost-effectiveness in the detection of renal artery stenosis. J Gen Intern Med 1988; 3:344-50
40. Brownell KD, Kaye FS. A school-based behavior modification, nutrition, education, and physical activity program for obese children. Am J Clin Nutr 1982; 35:277
41. Brownell KD, Stunkard AJ, McKeon PE. Weight reduction at the worksite: a promise partially fulfilled. Am J Psychiatry 1985; 142:47
42. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA 1989; 261-75-9
43. Oster G, Huse DM, Delea TE, et al. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA 1986; 256:1315-18
44. Krumholz HM, Cohen BJ, Tsevat J, et al. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993; 22:1697-702
45. Taylor CB, Houston-Miller N, Killen JD, et al. Smoking cessation after acute myocardial infarction: effect of a nurse-managed intervention. Ann Intern Med 1990; 113:118-23
46. Aberg A, Bergstrand R, Johansson S, et al. Cessation of smoking after myocardial infarction: effects on mortality after 10 years. Br Heart J 1983; 49:416-22
47. Hulley SB, Walsh JMB, Newinan TB. Health policy on blood cholesterol: time to change directions. Circulation 1992; 86: 1026-29
48. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990; 323:1112-19
49. von Dohlen TW, Frank MJ. Presyncope and syncope. How to find the cause and avoid staggering costs. Postgrad Med 1989; 86:91, 94-6
50. Mozes B, Confino-Cohen R, Halkin H. Cost-effectiveness of in-hospital evaluation of syncope. Isr J Med Sci 1988; 24:302-6
51. Estrada C, Rosman H, Prosad N, et al. Role of telemetry monitoring in the nonintensive care unit. Am J Cardiol 1995; 76:960-5
52. Kessler DK, Kessler KM, Myerburg RJ. Ambulatory electrocardiography: a cost per management decision analysis. Arch Intern Med 1995; 155:165-69
53. Beck JR, Salem DN, Estes NA, et al. A computer based Markov decision analysis of the management of symptomatic bifasicular block: the threshold probability for pacing. J Am Coll Cardiol 1987; 9:920-35
54. Graboys TB, Lown B, Podrid P, et al. Long-term survival of patients with malignant ventricular arrhythmia treated with antiar-rhythmic drugs. Am J Cardiol 1982; 50:437-43
55. Roy D, Waxman H, Kienzle M, et al. Clinical characteristics and long-term follow-up in 119 survivors of cardiac arrest: relation to inducibility at electrophysiologic testing. Am J Cardiol 1983; 52:969-74
56. Mason JW for the ESVEM investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiar-rhythmic drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993; 329:445-51
57. Omoigui NA, Marcus FI, Mason JW, et al. Cost of initial therapy in the electrophysiological study versus ECG monitoring trial (ESVEM). Circulation 1995; 91:1070-76
58. Larsen GC, Mandis AS, Sonnenberg FA, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol 1992; 19:1323-34
59. Kupersmith J, Hogan A, Cnerrero P, et al. Evaluating and improving the cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J 1995; 130:507-15
60. Wever EFD, Hauer RNW, Schrijvers G, et al. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors: a randomized study. Circulation 1996; 93:489-96